FCN-437 / Fosun Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
FCN-437 / Fosun Pharma
CTR20201637: A clinical study to evaluate the safety and preliminary efficacy of FCN-437c in the treatment of female patients with ER-positive, HER2-negative advanced breast cancer

Completed
2
60
China
FCN-437 - Fosun Pharma
Chongqing Fuchang Pharmaceutical Research Co., Ltd./Shanghai Fushang Huichuang Pharmaceutical Research Co., Ltd.
ER-positive, HER2-negative advanced breast cancer
 
 
NCT05004142: Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin

Recruiting
2
70
RoW
FCN-437c+Fulvestrant, FCN-437c+Letrozole+Goserelin
Ahon Pharmaceutical Co., Ltd., Hebei Medical University Fourth Hospital, The First Hospital of Jilin University, Affiliated Hospital of Hebei University
Breast Neoplasms
12/21
06/23
NCT04488107: Safety, Tolerability, Pharmacokinetics and Antitumor Activity of FCN-437c

Recruiting
1/2
78
RoW
FCN-437c, Dose-escalation and expansion, Letrozole 2.5mg, Dose-escalation
Ahon Pharmaceutical Co., Ltd., Fudan University, Zhejiang Cancer Hospital, Sir Run Run Shaw Hospital
Breast Neoplasms
12/21
06/22

Download Options